0001193125-15-169066.txt : 20150603 0001193125-15-169066.hdr.sgml : 20150603 20150504162000 ACCESSION NUMBER: 0001193125-15-169066 CONFORMED SUBMISSION TYPE: CORRESP PUBLIC DOCUMENT COUNT: 1 FILED AS OF DATE: 20150504 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Sarepta Therapeutics, Inc. CENTRAL INDEX KEY: 0000873303 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 930797222 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: CORRESP BUSINESS ADDRESS: STREET 1: 215 FIRST STREET STREET 2: SUITE 415 CITY: CAMBRIDGE STATE: MA ZIP: 02142 BUSINESS PHONE: 617-274-4000 MAIL ADDRESS: STREET 1: 215 FIRST STREET STREET 2: SUITE 415 CITY: CAMBRIDGE STATE: MA ZIP: 02142 FORMER COMPANY: FORMER CONFORMED NAME: Sarepta Therapuetics, Inc. DATE OF NAME CHANGE: 20120712 FORMER COMPANY: FORMER CONFORMED NAME: AVI BIOPHARMA INC DATE OF NAME CHANGE: 19980930 FORMER COMPANY: FORMER CONFORMED NAME: ANTIVIRALS INC DATE OF NAME CHANGE: 19970123 CORRESP 1 filename1.htm CORRESP

May 4, 2015

VIA EDGAR

United States Securities and Exchange Commission

Division of Corporation Finance

100 F Street, N.E.

Washington, D.C. 20549

 

Attention: Jeffrey P. Riedler
Daniel Greenspan
Matthew Jones
          Re: Sarepta Therapeutics, Inc.
Post-Effective Amendment No. 3 to
Registration Statement on Form S-3
Filed March 2, 2015
File No. 333-184807

Ladies and Gentlemen:

Pursuant to Rule 461 under the Securities Act of 1933, as amended, Sarepta Therapeutics, Inc. (the “Company”) hereby respectfully requests that the effective date for its Post-Effective Amendment No. 3 to Registration Statement on Form S-3 (File No. 333-184807) (the “Registration Statement”) be accelerated by the Securities and Exchange Commission (the “Commission”) so that it will be declared effective by 4:00 p.m. Eastern Time on May 5, 2015 or as soon as possible thereafter.

The Company hereby acknowledges the position of the staff of the Commission (the “Staff”) that:

 

  (i) should the Commission or the Staff, acting pursuant to delegated authority, declare the filing effective, it does not foreclose the Commission from taking any action with respect to the filing;

 

  (ii) the action of the Commission or the Staff, acting pursuant to delegated authority, in declaring the filing effective, does not relieve the Company from its full responsibility for the adequacy and accuracy of the disclosure in the filing; and

 

  (iii) the Company may not assert Staff comments and the declaration of effectiveness as a defense in any proceeding initiated by the Commission or any person under the federal securities laws of the United States.

It would be appreciated if, as soon as the Registration Statement is declared effective, you would inform Sarah Davis of Ropes & Gray LLP, counsel to the Company, at (617) 235-4995.

Very truly yours,

Sarepta Therapeutics, Inc.

 

By:

/s/ David Tyronne Howton, Jr.

Name: David Tyronne Howton, Jr.
Title: Senior Vice President, General Counsel and Secretary